Table 2

 Comparison of clinical characteristics and post-discharge treatments of patients with LVEF <50% and ⩾50%

VariableLVEFp Value
<50% (n = 754)⩾50% (n = 498)
Data are mean (SD) or number (%).
Age (years)67.4 (12.2)72.3 (10.2)<0.0001
Sex
    Men522 (69.2%)245 (49.2%)<0.0001
    Women232 (30.8%)253 (50.8%)
Time in hospital (days)15.0 (12.0)13.6 (12.3)0.047
Risk factors
    Arterial hypertension389 (51.6%)304 (61.0%)<0.001
    Hyperlipaemia256 (34.0%)163 (32.7%)0.66
    Diabetes mellitus210 (27.9%)125 (25.1%)0.250
    Smoking269 (35.7%)121 (24.3%)<0.0001
Underlying cardiopathy<0.0001
    Ischaemic cardiopathy409 (54.2%)207 (41.6%)
    Valve disease95 (12.6%)165 (33.1%)
    Dilated cardiomyopathy116 (15.4%)0
    Other134 (17.8%)126 (25.3%)
Clinical signs
    NYHA class IV332 (44.0%)190 (38.2%)0.017
    Jugular vein congestion362 (48.0%)200 (40.2%)0.030
    Third heart sound149 (19.8%)16 (3.2%)<0.0001
Radiographic signs
    Cardiomegaly613 (81.3%)381 (76.5%)0.005
    Alveolar oedema118 (15.6%)34 (6.8%)<0.0001
ECG signs
    Sinus rhythm445 (59.0%)230 (46.2%)<0.0001
    Atrial fibrillation232 (30.8%)192 (38.6%)0.0049
    Pathological Q wave191 (25.3%)69 (13.9%)<0.0001
    LBBB159 (21.1%)37 (7.4%)<0.0001
Drug treatment
    Digoxin271 (36.0%)115 (23.1%)<0.0001
    Diuretics618 (82.0%)330 (66.3)<0.0001
    ACE inhibitors534 (70.8)251 (50.4%)<0.0001
    ARB40 (5.3%)25 (5.0%)0.842
    Spironolactone121 (16.0%)41 (8.2%)0.0007
    Nitrates361 (47.9%)184 (36.9%)0.0004
    Hydralazine43 (5.7%)16 (3.2%)0.056
    Vasodilators50 (6.6%)29 (5.8%)0.624
    Calcium antagonists82 (10.9%)155 (31.1%)<0.0001
    β Blockers233 (30.9%)118 (23.7%)0.011
    Amiodarone130 (17.3%)69 (13.9%)0.131
    Antiplatelet agents452 (60%)258 (51.8%)0.007
    Anticoagulants195 (25.9%)141 (28.3%)0.441